Compare Twist Bioscience Corp (TWST) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wells Fargo & Co — how do they compare? Twist Bioscience Corp trades at $163.25 (market cap $10.08B), while Wells Fargo & Co trades at $83.24 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 24.6× Twist Bioscience Corp's market cap, and Wells Fargo & Co pays a 2.44% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Wells Fargo & Co for 87 Days on average.
| TWST | WFC | |
|---|---|---|
Market Cap | $10.08B | $248.06B |
Volume | 4,229,037 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $205.00 | $96.40 |
52-Week Low | $25.45 | $73.42 |
Typical Hold Time | 27 Days | 87 Days |
Enterprise Value | $10.01B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Wells Fargo (WFC) trades at $83.16, up 3.61% today, showing resilience amid a bearish technical signal. The stock benefits from strong profitability with a 25.97% net margin and a modest P/E of 11.92, indicating potential undervaluation relative to earnings. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and a renewed mortgage servicing agreement with Intercontinental Exchange (Business Wire, 2026-09-29).
The outlook is cautiously optimistic, supported by analyst consensus targets near $99.13 and improving net interest income prospects from Fed rate hikes. Key risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and execution challenges amid leadership transitions like the chief risk officer's retirement (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
